The Par Health drug recall of argatroban injection matters most to the clinicians and pharmacists who use it. On 13 October 2026 Par Health announced a voluntary nationwide recall of 22 lots of the intravenous anticoagulant because particulate matter was found in some lots, and the US Food and Drug Administration posted the FDA notice on 14 October. The recall is at the hospital or user level. The company says it has received no reports of adverse events related to the recall.
This explainer covers what argatroban does, why particles in an intravenous drug are a problem, what the notice asks hospitals to do, and what it leaves unanswered.
Par Health drug recall: key takeaways
- What is recalled: Argatroban Injection 250 mg/2.5 mL (100 mg/mL), 22 lots, sold under the Par Health and Endo USA names.
- Why: particulate matter identified as cellulose, polystyrene, polyethylene terephthalate, stopper material and possibly stainless steel.
- Who is affected: wholesalers and hospital pharmacies, which are asked to stop use and distribution immediately.
- Reported harm: none, according to the company.
- Unanswered: how the particles got in, and which lots contain which material.
What argatroban does in the Par Health drug recall context
Argatroban is a direct thrombin inhibitor, a synthetic anticoagulant. A StatPearls review of argatroban says it was approved in 2000 for the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT) and the related thrombosis syndrome, and in 2002 as an anticoagulant for patients undergoing percutaneous coronary intervention (PCI) who have HIT or are at risk of it.
HIT is an immune reaction to heparin in which antibodies activate platelets and push the blood towards clotting. Because heparin must be stopped, patients need a different anticoagulant, and argatroban is one of those used. It is given as a continuous intravenous infusion, and the review notes a short half-life of about 39 to 51 minutes, with the effect typically wearing off within 2 to 4 hours of stopping the infusion. Those details explain why it is a hospital drug.
The review also describes how treatment is monitored. In HIT the usual test is the activated partial thromboplastin time (aPTT), with a target of 1.5 to 3 times the baseline value, not to exceed 100 seconds, checked about two hours after starting and after each dose change. During PCI the activated clotting time is used instead. Argatroban is cleared mainly by the liver, and in people with liver impairment its effects can last far longer, 6 to 20 hours according to the review. In practice this means that every infusion is a closely watched, hospital-based treatment, which is why quarantining a suspect vial quickly matters.
Why particles matter in an intravenous drug
Anything injected into a vein travels to the lungs first. The company’s notice says that giving the recalled product has a reasonable probability of causing life-threatening adverse health consequences, and it names three potential outcomes: blockage of blood vessels in the lungs (pulmonary emboli), blockage of other vessels that can cause tissue death and organ damage, and inflammation of vein walls that may lead to clotting. These are potential risks stated in the notice, not events that have occurred.
The mixture of materials also stands out. Cellulose, polystyrene and polyethylene terephthalate are plastics or plant-derived fibres, stopper material comes from the vial closure, and the notice adds that stainless steel is possible. The notice does not say which was found where.
What the Par Health drug recall asks hospitals to do
- Immediately stop using and distributing the 22 listed lots.
- Wait for or act on written notice from Par Health, which is arranging return of all inventory through Inmar, Inc.
- Notify any accounts or locations you supplied.
- Contact Inmar on 1-855-648-7909 (Monday to Friday, 9 a.m. to 5 p.m. Eastern) for returns.
- Report adverse events or complaints to Par Health on 1-800-828-9393, or through FDA MedWatch.
The two affected product codes (NDCs) are 42023-182-01, which covers 20 of the 22 lots by our count, and 42023-182-89, which covers two. The recalled stock was distributed between 30 December 2024 and 5 May 2026. The lot numbers and expiry dates are in the FDA notice, and pharmacy teams should check each vial against it.
What the notice does not say about the Par Health drug recall
- How the particulate matter was found, and by whom.
- Which material appeared in which lot.
- The root cause, or whether the manufacturing site or packaging is implicated.
- Whether hospitals will face shortages while the lots are removed.
- Any FDA classification of the recall’s risk level.
Risks and caveats for the Par Health drug recall
- This is a company-issued notice reposted by the FDA, so details may be updated.
- With no reported adverse events, the clinical impact so far is unknown.
- Clinicians, not patients, decide whether any change to therapy is needed; patients should not stop treatment on their own.
- Nothing in the notice suggests that other Par Health products are affected, but the company has had another particulate recall this month, which we cover separately.
In our assessment, the practical priority for hospitals is to find and quarantine every vial from the 22 lots quickly, since argatroban is used in urgent situations and stock may be held in several locations. The longer-term question is whether Par Health can explain the contamination and reassure customers about supply.
For other regulatory news, see our report on the FDA Fast Track status for SAB-142, or browse more pharmaceutical news.
What to watch next in the Par Health drug recall
- Any expansion of the lot list.
- A root-cause explanation from Par Health.
- FDA classification of the recall.
- Reports of adverse events through MedWatch.
Frequently asked questions
What is the Par Health drug recall?
A voluntary nationwide recall of 22 lots of Argatroban Injection 250 mg/2.5 mL over particulate matter, announced on 13 October and posted by the FDA on 14 October 2026.
Is argatroban safe to use after the Par Health drug recall?
The listed lots should not be used. Hospitals are asked to stop use of those lots immediately. Questions about a specific patient should go to the treating team.
What is argatroban used for?
It is an anticoagulant used for patients with heparin-induced thrombocytopenia and during certain heart procedures in patients with or at risk of it.
Were any patients harmed in the Par Health drug recall?
The company says it has not received any reports of adverse events related to this recall.
How can adverse events be reported?
To Par Health on 1-800-828-9393 or through FDA MedWatch.
How we reported this: we relied on the FDA recall notice of 14 October 2026 and a StatPearls review of argatroban. Figures labelled as ours are our own calculations. Last updated: 15 October 2026. This article is news reporting and not medical advice.
